IL6 and COVID-19: On the other hand, the effect of the anti-IL-6 monoclonal antibody tocilizumab on patients hospitalized with COVID-19 is more controversial, although tocilizumab use may be associated with a short-term mortality and a reduction in the need for mechanical ventilation [34, 35].